Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

This Phase II study is evaluating whether routine full-body imaging (systemic screening) after surgery should be performed in breast cancer patients who still have cancer in their lymph nodes after receiving pre-surgery chemotherapy (neoadjuvant chemotherapy). The goal is to find out whether this screening helps detect distant spread of cancer early enough to change treatment decisions. **You may be eligible if...** - You are at least 18 years old - You have been diagnosed with breast cancer with known hormone receptor (ER/PR) and HER2 status - You have cancer-positive lymph nodes remaining after completing at least 8 weeks of neoadjuvant chemotherapy and surgery - HER2-positive and triple-negative patients need at least one positive node; HR+/HER2-negative patients need two or more positive nodes after surgery **You may NOT be eligible if...** - You did not complete the required minimum chemotherapy before surgery - You have no lymph node involvement after surgery - Your cancer type does not meet the specific criteria for this study Talk to your doctor to see if this trial is right for you.